vs
Side-by-side financial comparison of ICU MEDICAL INC (ICUI) and KORN FERRY (KFY). Click either name above to swap in a different company.
KORN FERRY is the larger business by last-quarter revenue ($729.8M vs $540.7M, roughly 1.3× ICU MEDICAL INC). KORN FERRY runs the higher net margin — 9.9% vs -2.9%, a 12.8% gap on every dollar of revenue. On growth, KORN FERRY posted the faster year-over-year revenue change (7.0% vs -14.1%). KORN FERRY produced more free cash flow last quarter ($100.7M vs $36.0M). Over the past eight quarters, KORN FERRY's revenue compounded faster (3.8% CAGR vs -2.3%).
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
Korn Ferry is a management consulting firm headquartered in Los Angeles, California. It was founded in 1969 and as of 2019, operates in 111 offices in 53 countries and employs 8,198 people worldwide. Korn Ferry operates through four business segments: Consulting, Digital, Executive Search, Recruitment Process Outsourcing and Professional Search.
ICUI vs KFY — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $540.7M | $729.8M |
| Net Profit | $-15.7M | $72.4M |
| Gross Margin | 37.5% | — |
| Operating Margin | 1.0% | 13.5% |
| Net Margin | -2.9% | 9.9% |
| Revenue YoY | -14.1% | 7.0% |
| Net Profit YoY | 34.0% | 19.1% |
| EPS (diluted) | $-0.63 | $1.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $540.7M | $729.8M | ||
| Q3 25 | $537.0M | $715.5M | ||
| Q2 25 | $548.9M | $719.8M | ||
| Q1 25 | $604.7M | $676.5M | ||
| Q4 24 | $629.8M | $682.0M | ||
| Q3 24 | $589.1M | $682.8M | ||
| Q2 24 | $596.5M | $699.9M | ||
| Q1 24 | $566.7M | $676.9M |
| Q4 25 | $-15.7M | $72.4M | ||
| Q3 25 | $-3.4M | $66.6M | ||
| Q2 25 | $35.3M | $64.2M | ||
| Q1 25 | $-15.5M | $58.4M | ||
| Q4 24 | $-23.8M | $60.8M | ||
| Q3 24 | $-33.0M | $62.6M | ||
| Q2 24 | $-21.4M | $65.2M | ||
| Q1 24 | $-39.5M | $59.1M |
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
| Q4 25 | 1.0% | 13.5% | ||
| Q3 25 | 2.6% | 11.7% | ||
| Q2 25 | 1.9% | 14.5% | ||
| Q1 25 | 2.1% | 11.6% | ||
| Q4 24 | 6.0% | 12.8% | ||
| Q3 24 | 1.4% | 11.1% | ||
| Q2 24 | 1.3% | 11.9% | ||
| Q1 24 | -1.9% | 7.4% |
| Q4 25 | -2.9% | 9.9% | ||
| Q3 25 | -0.6% | 9.3% | ||
| Q2 25 | 6.4% | 8.9% | ||
| Q1 25 | -2.6% | 8.6% | ||
| Q4 24 | -3.8% | 8.9% | ||
| Q3 24 | -5.6% | 9.2% | ||
| Q2 24 | -3.6% | 9.3% | ||
| Q1 24 | -7.0% | 8.7% |
| Q4 25 | $-0.63 | $1.36 | ||
| Q3 25 | $-0.14 | $1.26 | ||
| Q2 25 | $1.43 | $1.19 | ||
| Q1 25 | $-0.63 | $1.10 | ||
| Q4 24 | $-0.97 | $1.14 | ||
| Q3 24 | $-1.35 | $1.17 | ||
| Q2 24 | $-0.88 | $1.25 | ||
| Q1 24 | $-1.63 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $801.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.1B | $1.9B |
| Total Assets | $4.1B | $3.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $801.1M | ||
| Q3 25 | — | $721.1M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $820.0M | ||
| Q4 24 | $308.6M | $735.5M | ||
| Q3 24 | $312.5M | $674.0M | ||
| Q2 24 | $302.6M | $983.7M | ||
| Q1 24 | $251.4M | $782.5M |
| Q4 25 | $2.1B | $1.9B | ||
| Q3 25 | $2.1B | $1.9B | ||
| Q2 25 | $2.1B | $1.9B | ||
| Q1 25 | $2.0B | $1.8B | ||
| Q4 24 | $2.0B | $1.8B | ||
| Q3 24 | $2.0B | $1.8B | ||
| Q2 24 | $2.0B | $1.7B | ||
| Q1 24 | $2.1B | $1.7B |
| Q4 25 | $4.1B | $3.7B | ||
| Q3 25 | $4.1B | $3.6B | ||
| Q2 25 | $4.1B | $3.9B | ||
| Q1 25 | $4.2B | $3.6B | ||
| Q4 24 | $4.2B | $3.5B | ||
| Q3 24 | $4.3B | $3.4B | ||
| Q2 24 | $4.3B | $3.7B | ||
| Q1 24 | $4.3B | $3.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.6M | $121.4M |
| Free Cash FlowOCF − Capex | $36.0M | $100.7M |
| FCF MarginFCF / Revenue | 6.6% | 13.8% |
| Capex IntensityCapex / Revenue | 4.6% | 2.8% |
| Cash ConversionOCF / Net Profit | — | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | $91.8M | $272.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.6M | $121.4M | ||
| Q3 25 | $56.7M | $-237.4M | ||
| Q2 25 | $11.2M | $255.8M | ||
| Q1 25 | $51.3M | $213.7M | ||
| Q4 24 | $40.2M | $122.0M | ||
| Q3 24 | $36.1M | $-227.2M | ||
| Q2 24 | $82.0M | $261.9M | ||
| Q1 24 | $45.8M | $164.0M |
| Q4 25 | $36.0M | $100.7M | ||
| Q3 25 | $27.6M | $-260.0M | ||
| Q2 25 | $-8.5M | $235.5M | ||
| Q1 25 | $36.7M | $196.4M | ||
| Q4 24 | $16.1M | $107.7M | ||
| Q3 24 | $16.2M | $-237.7M | ||
| Q2 24 | $62.5M | $250.0M | ||
| Q1 24 | $29.9M | $152.3M |
| Q4 25 | 6.6% | 13.8% | ||
| Q3 25 | 5.1% | -36.3% | ||
| Q2 25 | -1.5% | 32.7% | ||
| Q1 25 | 6.1% | 29.0% | ||
| Q4 24 | 2.6% | 15.8% | ||
| Q3 24 | 2.7% | -34.8% | ||
| Q2 24 | 10.5% | 35.7% | ||
| Q1 24 | 5.3% | 22.5% |
| Q4 25 | 4.6% | 2.8% | ||
| Q3 25 | 5.4% | 3.2% | ||
| Q2 25 | 3.6% | 2.8% | ||
| Q1 25 | 2.4% | 2.6% | ||
| Q4 24 | 3.8% | 2.1% | ||
| Q3 24 | 3.4% | 1.5% | ||
| Q2 24 | 3.3% | 1.7% | ||
| Q1 24 | 2.8% | 1.7% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | -3.56× | ||
| Q2 25 | 0.32× | 3.98× | ||
| Q1 25 | — | 3.66× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | -3.63× | ||
| Q2 24 | — | 4.02× | ||
| Q1 24 | — | 2.78× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
KFY
| Industrial | $234.0M | 32% |
| Technology Service | $104.5M | 14% |
| RPO | $92.3M | 13% |
| Digital | $91.2M | 13% |
| Consumer Goods | $85.0M | 12% |
| Executive Search EMEA | $52.2M | 7% |
| Education Non Profit And General | $43.2M | 6% |
| Executive Search Asia Pacific | $24.3M | 3% |
| Reimbursed Out Of Pocket Engagement Expenses | $8.1M | 1% |
